Mankind Pharma Limited has informed the Exchange regarding a press release dated November 06, 2025, titled "Press Release for Q2FY26".
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma has submitted a press release to the stock exchange dated November 06, 2025, covering its Q2 FY2026 (July–September 2025) results. The filing itself is only an intimation that the press release has been shared, and the detailed financials such as revenue, profit, and margins are not included in the headline. Retail investors should refer to the actual press release or the company's quarterly results filing for specific numbers and management commentary. Mankind Pharma is one of India's leading pharmaceutical companies, and Q2 results are typically a key indicator of its performance in the domestic formulations business.
This is a procedural intimation about an already-released quarterly update, so it is unlikely to trigger a fresh stock reaction on its own. Investors should track the actual Q2FY26 numbers (revenue growth, EBITDA margin, and profit) for any meaningful impact on the share price.